PD-1:PD-L Inhibitory Pathway Affects Both CD4(+) and CD8(+) T Cells and is Overcome by IL-2
Overview
Authors
Affiliations
Programmed death-1 (PD-1) is an immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptor expressed upon T cell activation. PD-1(-/-) animals develop autoimmune diseases, suggesting an inhibitory role for PD-1 in immune responses. Members of the B7 family, PD-L1 and PD-L2, are ligands for PD-1. This study examines the functional consequences of PD-1:PD-L engagement on murine CD4 and CD8 T cells and shows that these interactions result in inhibition of proliferation and cytokine production. T cells stimulated with anti-CD3/PD-L1.Fc-coated beads display dramatically decreased proliferation and IL-2 production, while CSFE analysis shows fewer cells cycling and a slower division rate. Costimulation with soluble anti-CD28 mAb can overcome PD-1-mediated inhibition by augmenting IL-2 production. However, PD-1:PD-L interactions inhibit IL-2 production even in the presence of costimulation and, thus, after prolonged activation, the PD-1:PD-L inhibitory pathway dominates. Exogenous IL-2 is able to overcome PD-L1-mediated inhibition at all times, indicating that cells maintain IL-2 responsiveness. Experiments using TCR transgenic CD4(+) or CD8(+) T cells stimulated with antigen-presenting cells expressing PD-L1 show that both T cell subsets are susceptible to this inhibitory pathway. However, CD8(+) T cells may be more sensitive to modulation by the PD-1:PD-L pathway because of their intrinsic inability to produce significant levels of IL-2.
Catalano T, Selvaggi F, Cotellese R, Aceto G Cancers (Basel). 2025; 17(5).
PMID: 40075600 PMC: 11899472. DOI: 10.3390/cancers17050752.
Zhang D, Shen C, Zhang W, Chen H, Zhao J Front Immunol. 2025; 16:1524497.
PMID: 40070839 PMC: 11893867. DOI: 10.3389/fimmu.2025.1524497.
Cell Model for Testing Pharmaceuticals Targeting Human PD-L1.
Shashkova O, Terekhina L, Malakhov I, Pinevich A, Vartanyan N, Avrov K Sovrem Tekhnologii Med. 2025; 16(5):5-15.
PMID: 39897068 PMC: 11784882. DOI: 10.17691/stm2024.16.5.01.
IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancer.
Somri-Gannam L, Meisel-Sharon S, Hantisteanu S, Bar-Noy T, Sigal E, Groisman G Front Oncol. 2024; 14:1410447.
PMID: 39450263 PMC: 11499063. DOI: 10.3389/fonc.2024.1410447.
Palmer J, Villavicencio K, Idris M, Baranyk I, Polycarp N, Dawson A iScience. 2024; 27(10):110908.
PMID: 39351197 PMC: 11440800. DOI: 10.1016/j.isci.2024.110908.